Real-Time Breath Analysis in Acute Myeloid Leukaemia for a Rapid Characterisation of Biological Subtypes and to Predict Therapy Responses

Exhalomics for Phenotyping and Real-Time Stratification in Acute Myeloid Leukaemia (EXHALE)

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07826897

Acronym

EXHALE

Enrollment

120

Registered

2026-09-17

Start date

2026-09-21

Completion date

2029-08-31

Last updated

2026-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AML

Keywords

Exhalomics, Breath Analysis, AML, Biomarker

Brief summary

Patients with acute myeloid leukaemia (AML) respond to treatment to differing degrees, owing to the biological diversity of the disease. The diagnostic tests currently available for identifying genetic alterations and selecting the best possible treatment usually take several days before a result is obtained. In our study, the investigators aim to determine whether breath analysis can detect metabolic products of the leukaemia that allow the disease to be classified rapidly. Participants will undergo additional blood tests and a breath analysis during their routine appointments. This will take place only during the 1st and 2nd treatment cycles. They will also be asked to complete a questionnaire about their state of health. In addition, the study team will collect further information on their state of health (type of leukaemia, type of treatment, other medications, vital signs) from their medical records. In total, participants will complete 4 such measurements before and during their treatment. The measurements will be coordinated with their outpatient appointments. No assessments will be carried out unless the participants are at the hospital in any case, and they will not have to attend the hospital more often because of their participation in this study.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of an acute myeloid leukaemia and undergoing treatment * OR undergoing autoHSCT for lymphoid/myeloma disease in remission

Exclusion criteria

* inability to perform brath analysis * anatomical barriers preventing use of the mouthpiece.

Design outcomes

Primary

Measure	Time frame	Description
A breath metabolite signature representing AML disease burden	8 weeks	A breath metabolite signature representing AML disease burden, and might represent novel AML subtypes or describe cancer metabolic status.

Countries

Switzerland

Contacts

CONTACTJeremy W Deuel, PD MD PhD

haematologie-onkologie@usz.ch+41 41 255 11 11

CONTACTKevin D Hofer, MD

haematologie-onkologie@usz.ch+41 255 11 11

PRINCIPAL_INVESTIGATORJeremy W Deuel, PD MD PhD

University of Zurich

Outcome results